Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related